SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
AE Industrial Partners converted 46,505.13 shares of Convertible Preferred Stock into 15,247,586 shares of common stock, eliminating all remaining Convertible Preferred Stock outstanding and materially increasing the common share count and diluting existing shareholders' ownership percentages.
View raw filing on EDGAR →Rocket Lab entered into an equity distribution agreement on May 20, 2026, authorizing the issuance and sale of up to $3 billion in common stock through multiple sales agents and forward sale mechanisms. This is a material dilutive issuance that would significantly affect shareholder equity and voting power. The agreement includes both direct share sales and forward sale agreements (Initially Priced and Collared Forward Transactions), all of which contemplate the eventual issuance of common stock to raise capital.
View raw filing on EDGAR →Shareholders approved a corporate name change from 'Investcorp AI Acquisition Corp.' to 'Libity' and an extension of the business combination deadline from May 12, 2027 to May 12, 2028, with 99.6% of outstanding shares voting in favor. Following the extension, 11,896 Class A ordinary shares were redeemed by shareholders, with proceeds drawn from the trust account.
View raw filing on EDGAR →The filing discloses both a director departure (Andres Small's resignation) and a director appointment (Rachael Wagner's appointment to the Board as a Class III director). While both events occurred on the same date, the appointment is the principal forward-looking action and receives substantive disclosure (independence determination, compensation terms, board composition post-appointment). The appointment of a new independent director to a 12-member board is material to investors assessing board composition and governance.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting held on May 19, 2026. The filing reports the final voting outcomes for three proposals: election of five directors, ratification of RSM US LLP as independent auditor, and approval of an amendment to the Stock Incentive Plan to increase authorized shares to 13,000,000. This is a textbook Item 5.07 disclosure with specific vote tallies for each proposal.
View raw filing on EDGAR →The filing discloses an unregistered sale of approximately 580,074 shares of common stock for $9.4 million pursuant to subscription agreements and Section 4(a)(2)/Regulation D exemptions. This is a classic private placement equity issuance that dilutes existing shareholders and raises capital, fitting the dilutive_issuance category. The material amount ($9.4 million) and significant share count make this material to investors assessing ownership and capitalization.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final voting results from Solventum's annual shareholder meeting held on May 15, 2026. The filing presents tabulated results for three proposals: election of four Class II directors, advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. Shareholder vote results are material to investors as they reflect governance outcomes and stakeholder approval of key corporate matters.
View raw filing on EDGAR →The filing discloses a failure to satisfy Nasdaq Listing Rule 5605(c)(2)(A) following Daniel Hennessy's resignation from the Audit Committee, which reduced the committee below the required three independent members. Although the Company subsequently regained compliance on May 15, 2026 through Bruce Brown's appointment and Nasdaq confirmed restoration of compliance on May 19, 2026, the Item 3.01 disclosure itself documents the delisting risk event and its resolution. This is material to investors as it reflects governance compliance issues and potential listing jeopardy.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Newsmax Inc.'s 2026 Annual Meeting of Stockholders held on May 18, 2026, filed under Item 5.07. The section reports voting outcomes for two proposals: election of seven directors and ratification of BDO USA, P.C. as independent auditor, with detailed vote tallies (For, Against, Withheld, Abstentions, and Broker Non-Votes). This is a routine but material disclosure required by Item 5.07 of Form 8-K.
View raw filing on EDGAR →FirstEnergy Transmission entered into a Fifth Amended and Restated LLC Agreement on May 20, 2026, which implements governance arrangements for FET's participation in two new transmission joint ventures ("Valley Link" and "Grid Growth"). While the agreement itself does not modify ownership percentages or core governance rights, it formalizes FET's entry into material joint venture arrangements and extends the existing governance framework to these new ventures. This constitutes entry into material definitive agreements governing significant business combinations or joint ventures, which falls under M&A activity.
View raw filing on EDGAR →This Item 8.01 disclosure covers multiple routine fund operations: a declared dividend of $0.20 per Class I Share, net asset value reporting ($25.76 per share, $104.2 million total), portfolio composition (39 companies, $215.7 million fair value), and ongoing public offering status. While dividend declarations and NAV updates are standard for closed-end funds and typically immaterial, the combination of material portfolio metrics, leverage ratios (1.15x debt-to-equity), and continuous offering activity could affect investor assessment. However, no single event (earnings, impairment, covenant breach, or executive change) fits the specific taxonomy, making "other_material" the most appropriate classification for this routine but comprehensive fund update.
View raw filing on EDGAR →The filing discloses AEVEX Corp.'s financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1 under Item 2.02. This is a standard quarterly earnings release disclosure, which is material to investors as it provides key financial performance information.
View raw filing on EDGAR →This disclosure announces a spin-off of Enviri's Harsco Environmental and Harsco Rail segments into a separate publicly traded company and the sale of the Clean Earth segment. These are material corporate restructuring transactions involving the disposition of significant business segments and creation of a new public entity, which directly impacts the registrant's capital structure and operations. The announcement of timing and trading details for both parent and new company shares confirms this is a completed or imminent material acquisition/disposition event.
View raw filing on EDGAR →Stockholders approved the 2026 Long-Term Incentive Plan at the May 13, 2026 Annual Meeting, establishing a material equity incentive plan for officers and directors that affects executive compensation structure and potential dilution.
View raw filing on EDGAR →Results of the May 13, 2026 Annual Meeting of stockholders were disclosed, reporting voting outcomes on nine proposals including director elections, auditor ratification, executive compensation advisory vote, charter amendments, equity plan approval, and a stockholder proposal.
View raw filing on EDGAR →Analog Devices announced entry into a definitive agreement to acquire Empower Semiconductor, a provider of integrated voltage regulators and power management solutions. The transaction is material M&A activity expected to close in H2 2026, subject to Hart-Scott-Rondino antitrust clearance. This is a clear acquisition announcement that would materially affect investor assessment of the registrant's strategic direction and financial position.
View raw filing on EDGAR →Capital Southwest Corporation amended its at-the-market (ATM) offering program on May 19, 2026, increasing the maximum aggregate offering amount from $1.0 billion to $2.0 billion through sixth amendments to equity distribution agreements with four sales agents (Jefferies, Raymond James, Citizens Capital Markets, and B. Riley). This is a material dilutive issuance under Item 1.01, as it substantially expands the company's capacity to issue common stock and would materially affect shareholder equity and voting power.
View raw filing on EDGAR →This is a standard Item 5.07 disclosure of shareholder meeting results held on May 18, 2026. The filing reports voting outcomes on three matters: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent accountants, and a non-binding say-on-pay proposal that notably failed to receive majority support (4.4M for vs. 6.9M against). The failure of the executive compensation proposal is material to investors as it signals shareholder dissatisfaction with compensation practices.
View raw filing on EDGAR →David B. Mitchell, II, Chief Wholesale Banking Officer of F.N.B. Corporation, announced his intention to retire effective July 2, 2026. This is a clear departure of a named officer, making exec_departure the appropriate classification. The retirement of a C-suite executive responsible for wholesale banking operations is material to investors assessing management continuity and operational leadership.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Ford Motor Company's Annual Meeting of Shareholders held on May 14, 2026, covering six proposals: director elections, auditor ratification, say-on-pay advisory vote, recapitalization plan, voting disclosure, and DEI by-law amendment. Item 5.07 explicitly requires disclosure of shareholder vote results, and the detailed tabulation of votes for and against each proposal is the core content of this filing.
View raw filing on EDGAR →Humana Inc. entered into material definitive agreements on May 15, 2026, establishing a $1.5 billion pre-capitalized trust securities facility with Horseshoe Funding Trust I and II that provides on-demand capital and liquidity through the issuance of up to $750 million in Senior Notes to each trust over extended periods (10 and 30 years respectively). This material capital structure transaction involves the creation of direct financial obligations and represents a significant financing arrangement.
View raw filing on EDGAR →Ali El-Haj was appointed as President, Chief Executive Officer, and Director of Rogers Corporation, effective immediately on May 19, 2026, transitioning from Interim President and CEO to permanent roles. The appointment includes compensation details including a base salary of $750,000, target incentive of 100% of base, and a $5,000,000 long-term equity grant.
View raw filing on EDGAR →The filing discloses the appointment of Carrie Anderson as Executive Vice President and Chief Financial Officer effective July 1, 2026, succeeding retiring Charles T. Lauber. While the section also mentions Lauber's retirement, the principal disclosed action centers on Anderson's appointment to a C-suite role, supported by detailed background, compensation terms ($1.5M RSU award), and benefit arrangements. This is a material executive appointment at a major industrial company.
View raw filing on EDGAR →The filing discloses the appointment of Thomas Dittrich as Executive Vice President and Chief Financial Officer effective September 1, 2026, along with detailed compensation arrangements including base salary (CHF 1,070,000), equity grants (CHF 4,500,000 target), sign-on RSU award (CHF 4,700,000), and retention bonus (CHF 5,800,000). While the section also mentions Peter Griffith's retirement, the substantive focus and length of disclosure centers on Dittrich's appointment and his comprehensive compensation package, making this primarily an exec_appointment event. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance.
View raw filing on EDGAR →The Company issued a press release on May 19, 2026 announcing financial results for the fiscal quarter ended May 3, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard quarterly earnings release disclosure, which is material to investors as it provides key financial performance metrics and operational results.
View raw filing on EDGAR →The filing discloses both a director retirement (Gary Lehman) and a director appointment (Paul Fultz). While both events are mentioned, the appointment is the principal forward-looking action: Fultz was appointed to fill the vacancy and will serve on the Audit Committee. The explicit statement that Lehman's retirement "is not the result of any disagreement" suggests a routine transition, making the appointment the more salient event. Director changes are material to investors assessing board composition and governance.
View raw filing on EDGAR →The filing discloses results of operations for the three-month and six-month periods ended April 30, 2026 via a press release attached as Exhibit 99.1, which is the classic structure of an earnings release under Item 2.02. This is material to investors as it provides periodic financial performance data essential to assessing the registrant's financial condition and results.
View raw filing on EDGAR →The filing discloses compensatory arrangements for three named executive officers: salary increases (ranging from $9,100 to $11,024) and equity awards of 500 immediately-vesting restricted shares each, approved by the Compensation Committee on May 14, 2026. This is a direct disclosure of executive compensation modifications under Item 5.02(e), distinct from any departure or appointment.
View raw filing on EDGAR →Teradata held its Annual Meeting of Stockholders on May 14, 2026, with voting results on four matters: election of three Class I directors (Melissa B. Fisher, Stephen McMillan, and Kimberly K. Nelson), an advisory say-on-pay vote, approval of the Amended 2023 Stock Incentive Plan increasing available shares by 6,300,000, and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from WSFS Financial Corporation's 2026 Annual Meeting held on May 14, 2026. The filing reports voting outcomes on three proposals: election of three directors (Eleuthère I. du Pont, Michelle Hong, and David G. Turner), advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the hallmark of Item 5.07 shareholder vote disclosures.
View raw filing on EDGAR →Farmer Mac completed an issuance of 4,000,000 shares of preferred stock in an exempt public offering on May 19, 2026. While this is a preferred stock issuance rather than common equity, it represents a material capital raise that dilutes existing shareholders' ownership and is typically disclosed under Item 3.02 (Unregistered Sales) or Item 8.01 (Other Events). The issuance of 4 million shares of preferred stock with a stated dividend rate (6.875%) is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →Merit Medical Systems held its Annual Meeting of Shareholders on May 13, 2026, with detailed voting results reported for five proposals: election of four directors, an advisory say-on-pay vote, approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, and ratification of the independent auditor.
View raw filing on EDGAR →Scott R. Ward was elected as a director of Merit Medical Systems Inc., as announced via press release on Form 8-K.
View raw filing on EDGAR →Shareholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, and the Board approved a Restricted Stock Unit Award Agreement for directors, establishing compensatory arrangements for officers and directors.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Bausch Health's Annual Meeting of Shareholders held on May 19, 2026. The filing reports voting outcomes on three proposals: election of directors (including new director Eiry W. Roberts, M.D.), advisory vote on executive compensation, and appointment of PricewaterhouseCoopers LLP as auditors. This is a quintessential Item 5.07 disclosure with detailed voting tallies for each matter.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Annual Meeting of Shareholders held on May 19, 2026. The filing reports voting outcomes for three proposals: election of seven directors, advisory vote on named executive officer compensation, and ratification of Grant Thornton LLP as independent auditor. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →Richard H. Raborn, Executive Vice President of the Vegetation Management Division, is retiring effective May 29, 2026. While the disclosure also includes severance terms (base salary of $536,000 paid over 12 months), the principal disclosed action is the departure itself. The filing emphasizes the retirement and separation, making exec_departure the most salient classification, though the compensation component is secondary.
View raw filing on EDGAR →The Board approved and adopted an Amended and Restated Annual Incentive Plan on May 13, 2026, making administrative and technical updates to the compensation plan structure. This is a compensatory arrangement disclosure under Item 5.02(e), involving amendments to a bonus incentive plan that affects how participating employees—including Named Executive Officers—receive performance-based compensation. The amendments clarify delegation authority and align the plan with the 2025 Stock Incentive Plan.
View raw filing on EDGAR →FB Bancorp completed a stock repurchase program that retired 10% of outstanding shares at an average price of $13.717 per share. While share repurchases are capital allocation events that affect shareholder equity and EPS, they do not fit neatly into the more specific event categories (not an earnings release, M&A, impairment, or executive change). This is material to investors as it reflects management's capital deployment strategy and impacts share count, but lacks a dedicated taxonomy entry.
View raw filing on EDGAR →The filing discloses financial results for the quarter and fiscal year ended March 31, 2026 through a press release and stockholder letter with financial highlights, furnished as exhibits. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly and annual financial performance information.
View raw filing on EDGAR →David L. Duvall, the Company's President and Chief Executive Officer, is transitioning out of his executive role effective June 1, 2026, under a Transition Agreement. While the agreement includes a consulting arrangement with compensatory terms ($50,000 monthly fee through December 31, 2027), the principal disclosed action is the departure of the CEO from his operational role. The departure of a sitting CEO is material to investors assessing management continuity and company direction.
View raw filing on EDGAR →Celestica Inc. held its 2026 annual meeting of shareholders on May 19, 2026, with voting results disclosed on three matters: election of nine directors, approval of auditor appointment, and an advisory vote on named executive officer compensation. The filing reports final voting tallies for each matter.
View raw filing on EDGAR →FormFactor held its Annual Meeting of Stockholders on May 15, 2026, at which stockholders voted on five proposals: election of seven directors, amendment to the Certificate of Incorporation, advisory vote on executive compensation, amendment to the 2012 Equity Incentive Plan increasing the share reserve by 5,000,000 shares, and ratification of the independent auditor. All proposals were approved by stockholders.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from YUM! Brands' Annual Meeting of Shareholders held on May 14, 2026, filed under Item 5.07. The filing reports voting outcomes on four matters: election of 11 directors, ratification of KPMG LLP as independent auditor, advisory vote on executive compensation, and a shareholder proposal on special meeting thresholds. All vote tallies (for, against, abstain, broker non-votes) are provided for each matter, which is the standard format for Item 5.07 disclosures.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of Amkor Technology's Annual Meeting of Stockholders held on May 13, 2026, including voting outcomes on three proposals: election of 11 directors, advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed. This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →American Tower Corporation announced the pricing of a €750 million registered public offering of senior unsecured notes due 2033 at 4.000% per annum. This is a material debt issuance that would affect investor assessment of the company's capital structure and financing activities, but it does not fit neatly into the more specific event categories (it is neither a dilutive equity issuance under Item 3.02, nor an M&A activity, nor a covenant breach). The disclosure is appropriately classified as other_material.
View raw filing on EDGAR →HIVE Digital's wholly owned subsidiary BUZZ High Performance Computing completed the acquisition of two parcels of land totaling $58 million ($46 million for the Main Parcel and $12 million for the Additional Parcel) with a combined 320 MW power allocation. This represents a material acquisition of real property and infrastructure assets that would be significant to investors evaluating the company's capital deployment and operational expansion strategy.
View raw filing on EDGAR →InMed Pharmaceuticals amended preferred investment options with Armistice Capital, reducing the exercise price from $16.60 to $0.80 per share on 278,761 common shares. This substantial downward repricing converts out-of-the-money warrants into deeply in-the-money instruments, significantly increasing the likelihood of exercise and dilution to existing shareholders.
View raw filing on EDGAR →The Board approved debt-to-equity conversion agreements with four creditors (including the CEO and VP Administration) whereby the Company will issue 1,509,710 common shares in aggregate to settle approximately C$1.24 million in deferred management fees, subject to regulatory approvals and shareholder vote.
View raw filing on EDGAR →The Company granted 100,000 stock options to an officer on May 18, 2026, exercisable at C$0.82 per share for five years, pursuant to the Company's Long-Term Incentive Plan.
View raw filing on EDGAR →